The extracellular matrix’s excess deposition in the cardiac muscle is commonly referred as cardiac fibrosis. This term is also known as heart valves’ abnormal thickening because of inappropriate proliferation of cardiac fibroblasts. Various drugs are widely used to prevent or target cardiac fibrosis.
Surging heart failures in the huge population across many countries is one of the prominent factors likely to boost the sales of cardiac fibrosis drugs. Many factors such as harmful lifestyle habits, smoking, unhealthy diet, and lack of physical activities, are attributed to the expanding cases of heart failure. For instance, around 5 million Americans are suffering from congestive heart failure recently. In the U.S., every year, nearly 550,000 new cases are diagnosed. Increasing heart failure has enhanced the demand for cardiac fibrosis drugs. These drugs help to reduce the growing incidence of heart failure and aid to develop the overall heart function. As a result, this factor is dramatically bolstering the growth of market throughout the globe. In addition to this, rising healthcare expenditure mostly in developed countries is another growth factor influencing the market’s growth globally.
Evolving technologies in the healthcare sector has improved the government’s as well as private company’s spending. For example, hospital expenditures increased 4.4% to $1,323.9 billion as per the report published by Centers for Medicare & Medicaid Services. This increased spending on the healthcare sector has resulted in rocketing R&D regarding various drugs, treatments, vaccines, and latest technologies. This is further heightening the development in fibrosis drugs as well. Consequently, this factor is driving the market’s expansion across the global. Similarly, government initiatives for the drug discovery and development are also assisting the market to propel the global revenue.
Despite aforementioned growth factors, high development cost for cardiac fibrosis drugs is destructively impacting on the growth of global market. Similarly, time-consuming process for drug approval and clinical trials is also hampering the growth of market globally. Furthermore, many government organizations as well as private businesses are highly investing in the technological advancement in the market. This factor is generating pockets of opportunities for the market to expand with fastest pace in the upcoming years.
New product launches to flourish in the market
In September 2021, the galectin-3 inhibitor GB1211 has been administered to the first patient in the Phase 1b/2a GULLIVER-2 trial, according to a statement from Galecto, Inc., a publicly traded firm that focuses on the discovery of new therapies for fibrosis and cancer. The Galecto clinical programme for GB1211 in liver cirrhosis officially begins with this trial. In addition to this, in April 2022, The Phase IIb GALACTIC-1 clinical trial of GB0139 to treat idiopathic pulmonary fibrosis (IPF) has reached its subject enrollment cap, according to Galecto. At about 100 locations globally, the double-blind, randomised, placebo-controlled, parallel-group experiment is being conducted. In 141 IPF patients, the safety and effectiveness of GB0139 will be examined. Ongoing clinical trials on the fibrosis drugs are trending across the market. Drug development is gaining huge opportunities among several industry participants and this is fostering the demand for cardiac fibrosis drugs globally.
The cardiac fibrosis drug market is segmented on the basis of drug type, route of administration, molecular type, and region. By drug type, it is divided into galectin 3, lysyl oxidase homolog 2, and others. By route of administration, it is divided into oral and intravenous. By molecular type, it is divided into small monoclonal antibody, polysaccharide, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Overview:
By drug type: The cardiac fibrosis drug market is categorized into galectin 3, lysyl oxidase homolog 2, and others. By facilitating collagen cross-links, epithelial to mesenchymal transition and myofibroblast activation, lysyl oxidase-like 2 is recognized to play important roles in ECM stabilisation. In addition, galectin 3 drug type is one of the crucial biomarker of myocardial fibrosis and ventricular remodelling. It is also an essential regulator of acute inflammatory and chronic condition resulting to fibrosis.
By route of administration: The cardiac fibrosis drug market is divided into oral and intravenous. The drugs significantly used for the treatment for cardiac fibrosis, heart failures, and many other diseases can administrated either by oral or by intravenous. The drugs taken intravenously assures as 100% bioavailability, while oral administration takes longer route to be effective.
By molecular type: The cardiac fibrosis drug market is classified into small monoclonal antibody, polysaccharide, and others. Many other molecular types such as antibody, synthetic peptide, oligonucleotide, and recombinant protein are also involved in this type of segment.
By region: North America is projected to account largest share of the global revenue in the fiscal year of 2021. This is majorly attributed to increasing cardiovascular diseases in the North American countries. These diseases are leading cause of death among population of this region. For example, as per the report released by the Centers for Disease Control and Prevention, in every 34 seconds one person dies from cardiovascular diseases in U.S. of America. Also, over 7 million people died from heart diseases in year 2020. As incidences of cardiac fibrosis increases, the need for effective treatment also rises. This enhances the sales of drugs and medications. Subsequently, booming cases of cardiovascular diseases is likely to spur the market in the North America region.
Competitive analysis and profiles of the major players in the cardiac fibrosis drug market, such as Evotec SE, Galectin Therapeutics Inc., Guangdong Maijinjia Biotechnologies Co. Ltd, InvivoSciences Inc., Lead Discovery Center GmbH, MandalMed Inc, NovoMedix LLC, Palatin Technologies Inc, Pharmaxis Ltd, and Puretech Health Plc. are provided in this report.
Surging heart failures in the huge population across many countries is one of the prominent factors likely to boost the sales of cardiac fibrosis drugs. Many factors such as harmful lifestyle habits, smoking, unhealthy diet, and lack of physical activities, are attributed to the expanding cases of heart failure. For instance, around 5 million Americans are suffering from congestive heart failure recently. In the U.S., every year, nearly 550,000 new cases are diagnosed. Increasing heart failure has enhanced the demand for cardiac fibrosis drugs. These drugs help to reduce the growing incidence of heart failure and aid to develop the overall heart function. As a result, this factor is dramatically bolstering the growth of market throughout the globe. In addition to this, rising healthcare expenditure mostly in developed countries is another growth factor influencing the market’s growth globally.
Evolving technologies in the healthcare sector has improved the government’s as well as private company’s spending. For example, hospital expenditures increased 4.4% to $1,323.9 billion as per the report published by Centers for Medicare & Medicaid Services. This increased spending on the healthcare sector has resulted in rocketing R&D regarding various drugs, treatments, vaccines, and latest technologies. This is further heightening the development in fibrosis drugs as well. Consequently, this factor is driving the market’s expansion across the global. Similarly, government initiatives for the drug discovery and development are also assisting the market to propel the global revenue.
Despite aforementioned growth factors, high development cost for cardiac fibrosis drugs is destructively impacting on the growth of global market. Similarly, time-consuming process for drug approval and clinical trials is also hampering the growth of market globally. Furthermore, many government organizations as well as private businesses are highly investing in the technological advancement in the market. This factor is generating pockets of opportunities for the market to expand with fastest pace in the upcoming years.
New product launches to flourish in the market
In September 2021, the galectin-3 inhibitor GB1211 has been administered to the first patient in the Phase 1b/2a GULLIVER-2 trial, according to a statement from Galecto, Inc., a publicly traded firm that focuses on the discovery of new therapies for fibrosis and cancer. The Galecto clinical programme for GB1211 in liver cirrhosis officially begins with this trial. In addition to this, in April 2022, The Phase IIb GALACTIC-1 clinical trial of GB0139 to treat idiopathic pulmonary fibrosis (IPF) has reached its subject enrollment cap, according to Galecto. At about 100 locations globally, the double-blind, randomised, placebo-controlled, parallel-group experiment is being conducted. In 141 IPF patients, the safety and effectiveness of GB0139 will be examined. Ongoing clinical trials on the fibrosis drugs are trending across the market. Drug development is gaining huge opportunities among several industry participants and this is fostering the demand for cardiac fibrosis drugs globally.
The cardiac fibrosis drug market is segmented on the basis of drug type, route of administration, molecular type, and region. By drug type, it is divided into galectin 3, lysyl oxidase homolog 2, and others. By route of administration, it is divided into oral and intravenous. By molecular type, it is divided into small monoclonal antibody, polysaccharide, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Overview:
By drug type: The cardiac fibrosis drug market is categorized into galectin 3, lysyl oxidase homolog 2, and others. By facilitating collagen cross-links, epithelial to mesenchymal transition and myofibroblast activation, lysyl oxidase-like 2 is recognized to play important roles in ECM stabilisation. In addition, galectin 3 drug type is one of the crucial biomarker of myocardial fibrosis and ventricular remodelling. It is also an essential regulator of acute inflammatory and chronic condition resulting to fibrosis.
By route of administration: The cardiac fibrosis drug market is divided into oral and intravenous. The drugs significantly used for the treatment for cardiac fibrosis, heart failures, and many other diseases can administrated either by oral or by intravenous. The drugs taken intravenously assures as 100% bioavailability, while oral administration takes longer route to be effective.
By molecular type: The cardiac fibrosis drug market is classified into small monoclonal antibody, polysaccharide, and others. Many other molecular types such as antibody, synthetic peptide, oligonucleotide, and recombinant protein are also involved in this type of segment.
By region: North America is projected to account largest share of the global revenue in the fiscal year of 2021. This is majorly attributed to increasing cardiovascular diseases in the North American countries. These diseases are leading cause of death among population of this region. For example, as per the report released by the Centers for Disease Control and Prevention, in every 34 seconds one person dies from cardiovascular diseases in U.S. of America. Also, over 7 million people died from heart diseases in year 2020. As incidences of cardiac fibrosis increases, the need for effective treatment also rises. This enhances the sales of drugs and medications. Subsequently, booming cases of cardiovascular diseases is likely to spur the market in the North America region.
Competitive analysis and profiles of the major players in the cardiac fibrosis drug market, such as Evotec SE, Galectin Therapeutics Inc., Guangdong Maijinjia Biotechnologies Co. Ltd, InvivoSciences Inc., Lead Discovery Center GmbH, MandalMed Inc, NovoMedix LLC, Palatin Technologies Inc, Pharmaxis Ltd, and Puretech Health Plc. are provided in this report.
Cardiac Fibrosis Drug Market, by Drug Type Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Route of Administration |
|
 By Molecule Type |
|
 By Region |
|
 Key Market Players | Guangdong Maijinjia Biotechnologies Co Ltd, Pharmaxis Ltd, Invivosciences Inc., Palatin Technologies Inc, Galectin Therapeutics Inc., Evotec SE, NovoMedix LLC, Puretech Health Plc, MandalMed Inc, lead discovery center gmbh |
Loading Table Of Content...
